https://www.selleckchem.com/products/zn-c3.html
Overall 5-year survival was 85.4% and recurrence-free survival was 83.3% after a median follow-up of 35months (13-59). This was similar to LDLT for other indications (81.2% at 5years). Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score was best able to predict recurrence (p = 0.03) with odds ratio of 6.8. Patients with HCC in India present late for liver transplant. Most patients have some form of decompensation before they undergo LT. In selected patients, overall survival was comparable with other indications for LDLT
Like
Comment
Share
